198 related articles for article (PubMed ID: 32034196)
21. Assessment of the clinical application of detecting EGFR, KRAS, PIK3CA and BRAF mutations in patients with non-small cell lung cancer using next-generation sequencing.
Xu X; Yang Y; Li H; Chen Z; Jiang G; Fei K
Scand J Clin Lab Invest; 2016 Sep; 76(5):386-92. PubMed ID: 27215271
[TBL] [Abstract][Full Text] [Related]
22. Clinical and Pathological Characteristics of
Frank R; Scheffler M; Merkelbach-Bruse S; Ihle MA; Kron A; Rauer M; Ueckeroth F; König K; Michels S; Fischer R; Eisert A; Fassunke J; Heydt C; Serke M; Ko YD; Gerigk U; Geist T; Kaminsky B; Heukamp LC; Clement-Ziza M; Büttner R; Wolf J
Clin Cancer Res; 2018 Jul; 24(13):3087-3096. PubMed ID: 29615460
[No Abstract] [Full Text] [Related]
23. Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer.
Jing C; Mao X; Wang Z; Sun K; Ma R; Wu J; Cao H
Mol Med Rep; 2018 Aug; 18(2):2191-2197. PubMed ID: 29956783
[TBL] [Abstract][Full Text] [Related]
24. Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases.
Volckmar AL; Leichsenring J; Kirchner M; Christopoulos P; Neumann O; Budczies J; Morais de Oliveira CM; Rempel E; Buchhalter I; Brandt R; Allgäuer M; Talla SB; von Winterfeld M; Herpel E; Goeppert B; Lier A; Winter H; Brummer T; Fröhling S; Faehling M; Fischer JR; Heußel CP; Herth F; Lasitschka F; Schirmacher P; Thomas M; Endris V; Penzel R; Stenzinger A
Int J Cancer; 2019 Aug; 145(3):649-661. PubMed ID: 30653256
[TBL] [Abstract][Full Text] [Related]
25. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
Li Y; Zhang FS; Guo L; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
[No Abstract] [Full Text] [Related]
26. Genomic characteristics of driver genes in Chinese patients with non-small cell lung cancer.
Si X; Pan R; Ma S; Li L; Liang L; Zhang P; Chu Y; Wang H; Wang M; Zhang X; Zhang L
Thorac Cancer; 2021 Feb; 12(3):357-363. PubMed ID: 33300283
[TBL] [Abstract][Full Text] [Related]
27. High-throughput diagnostic profiling of clinically actionable gene fusions in lung cancer.
Pfarr N; Stenzinger A; Penzel R; Warth A; Dienemann H; Schirmacher P; Weichert W; Endris V
Genes Chromosomes Cancer; 2016 Jan; 55(1):30-44. PubMed ID: 26394895
[TBL] [Abstract][Full Text] [Related]
28. Characteristics of genomic alterations of lung adenocarcinoma in young never-smokers.
Luo W; Tian P; Wang Y; Xu H; Chen L; Tang C; Shu Y; Zhang S; Wang Z; Zhang J; Zhang L; Jiang L; Liu L; Che G; Guo C; Zhang H; Wang J; Li W
Int J Cancer; 2018 Oct; 143(7):1696-1705. PubMed ID: 29667179
[TBL] [Abstract][Full Text] [Related]
29. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
[TBL] [Abstract][Full Text] [Related]
30. Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.
Lee CK; Kim S; Lee JS; Lee JE; Kim SM; Yang IS; Kim HR; Lee JH; Kim S; Cho BC
Lung Cancer; 2017 Nov; 113():106-114. PubMed ID: 29110836
[TBL] [Abstract][Full Text] [Related]
31. Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia.
Loong HH; Raymond VM; Shiotsu Y; Chua DTT; Teo PML; Yung T; Skrzypczak S; Lanman RB; Mok TSK
Clin Lung Cancer; 2018 Sep; 19(5):e601-e608. PubMed ID: 29807856
[TBL] [Abstract][Full Text] [Related]
32. NGS Analysis of Liquid Biopsy (LB) and Formalin-Fixed Paraffin-Embedded (FFPE) Melanoma Samples Using Oncomine™ Pan-Cancer Cell-Free Assay.
Olbryt M; Rajczykowski M; Bal W; Fiszer-Kierzkowska A; Cortez AJ; Mazur M; Suwiński R; Widłak W
Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356096
[TBL] [Abstract][Full Text] [Related]
33. Discovery of targetable genetic alterations in advanced non-small cell lung cancer using a next-generation sequencing-based circulating tumor DNA assay.
Hou H; Yang X; Zhang J; Zhang Z; Xu X; Zhang X; Zhang C; Liu D; Yan W; Zhou N; Zhu H; Qian Z; Li Z; Zhang X
Sci Rep; 2017 Nov; 7(1):14605. PubMed ID: 29097733
[TBL] [Abstract][Full Text] [Related]
34. Targeted deep sequencing from multiple sources demonstrates increased NOTCH1 alterations in lung cancer patient plasma.
Liao Y; Ma Z; Zhang Y; Li D; Lv D; Chen Z; Li P; Ai-Dherasi A; Zheng F; Tian J; Zou K; Wang Y; Wang D; Cordova M; Zhou H; Li X; Liu D; Yu R; Zhang Q; Zhang X; Zhang J; Zhang X; Zhang X; Li Y; Shao Y; Song L; Liu R; Wang Y; Sufiyan S; Liu Q; Owen GI; Li Z; Chen J
Cancer Med; 2019 Sep; 8(12):5673-5686. PubMed ID: 31369215
[TBL] [Abstract][Full Text] [Related]
35. Clinical next-generation sequencing in patients with non-small cell lung cancer.
Hagemann IS; Devarakonda S; Lockwood CM; Spencer DH; Guebert K; Bredemeyer AJ; Al-Kateb H; Nguyen TT; Duncavage EJ; Cottrell CE; Kulkarni S; Nagarajan R; Seibert K; Baggstrom M; Waqar SN; Pfeifer JD; Morgensztern D; Govindan R
Cancer; 2015 Feb; 121(4):631-9. PubMed ID: 25345567
[TBL] [Abstract][Full Text] [Related]
36. Analysis of a large cohort of non-small cell lung cancers submitted for somatic variant analysis demonstrates that targeted next-generation sequencing is fit for purpose as a molecular diagnostic assay in routine practice.
Moore DA; Balbi K; Ingham A; Arkenau HT; Bennett P
J Clin Pathol; 2018 Nov; 71(11):1001-1006. PubMed ID: 30054375
[TBL] [Abstract][Full Text] [Related]
37. Frequency of Somatic TP53 Mutations in Combination with Known Pathogenic Mutations in Colon Adenocarcinoma, Non-Small Cell Lung Carcinoma, and Gliomas as Identified by Next-Generation Sequencing.
Shajani-Yi Z; de Abreu FB; Peterson JD; Tsongalis GJ
Neoplasia; 2018 Mar; 20(3):256-262. PubMed ID: 29454261
[TBL] [Abstract][Full Text] [Related]
38. Development and validation of an ultra-high sensitive next-generation sequencing assay for molecular diagnosis of clinical oncology.
Liang J; She Y; Zhu J; Wei L; Zhang L; Gao L; Wang Y; Xing J; Guo Y; Meng X; Li P
Int J Oncol; 2016 Nov; 49(5):2088-2104. PubMed ID: 27826616
[TBL] [Abstract][Full Text] [Related]
39. Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.
Malapelle U; Mayo de-Las-Casas C; Rocco D; Garzon M; Pisapia P; Jordana-Ariza N; Russo M; Sgariglia R; De Luca C; Pepe F; Martinez-Bueno A; Morales-Espinosa D; González-Cao M; Karachaliou N; Viteri Ramirez S; Bellevicine C; Molina-Vila MA; Rosell R; Troncone G
Br J Cancer; 2017 Mar; 116(6):802-810. PubMed ID: 28170370
[TBL] [Abstract][Full Text] [Related]
40. Comparison detection methods for EGFR in formalin-fixed paraffin-embedded tissues of patients with NSCLC.
Fan X; Wang X; Zhang M; Deng H; Liu Y
Pathol Res Pract; 2020 Jan; 216(1):152783. PubMed ID: 31859115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
